Executive Order 14411: New US Customs Rules for Importers

Executive Order 14411, signed on 3 June 2026 under the title Strengthening Customs Enforcement, represents the most significant overhaul of US customs rules in decades — and if you were fully compliant before June, that status may no longer hold.

The order eliminates informal entries entirely, restricts continuous bonds, mandates CTPAT-validated broker relationships, and introduces sweeping new disclosure requirements at the point of CBP entry. With the 180-day full implementation deadline falling in early December 2026, the window to restructure your customs setup is narrow.

• Formal entry now required for all shipments — informal entry thresholds abolished
• Continuous bonds restricted: CBP approval now required on a case-by-case basis
• CTPAT-validated broker mandatory — or direct CTPAT validation for your own entity
• New entry disclosures: beneficial ownership, manufacturer IDs, supply chain provenance and foreign tax identifiers
• Tougher penalties for misclassification and undervaluation with reduced mitigation relief
• FDA parallel inspection surge — compounded compliance risk for food, supplement and medical device importers Request a Compliance Gap Review Speak to Our US Customs Team

How Global Import Agent Helps You Navigate EO 14411

At Global Import Agent, we are already working with clients across the UK, EU and Asia to pressure-test their US import structures against the new requirements introduced by Executive Order 14411.

Our role is not to replace your customs broker — it is to sit above the process, identify the structural gaps in your current setup, and connect you with the right resources before the December 2026 enforcement deadline bites. We are trusted by over 500 brands for FDA Agent and FSVP compliance under the Food Safety Modernization Act.

That existing network — built around 21 CFR Part 1 Subpart L and Subpart H obligations — now extends into CBP customs compliance under EO 14411, giving our clients a single point of accountability across both regulatory frameworks simultaneously.

This matters because the order’s enforcement runs in parallel with an FDA surge of unannounced foreign facility inspections, meaning food, supplement, cosmetic and medical device importers face compounded risk from two federal agencies at once. Our approach covers:

• Reviewing your current Importer of Record (IOR) structure under the revised 19 USC 1484 framework
• Auditing your bond position — whether your continuous bond retains CBP approval under 19 CFR Part 113 or requires reclassification as a single-entry bond
• Identifying whether your existing customs broker holds CTPAT validation under 19 CFR Part 165, and sourcing a validated alternative where they do not

Mapping the new entry disclosure requirements — beneficial ownership, Manufacturer ID (MID), supply chain data and foreign tax identifiers — against what your current documentation provides Flagging HTS classification and valuation risk in light of the reduced mitigation pathways now available under the order.

• IOR Structure Review – We audit your existing Importer of Record arrangement against the revised 19 USC 1484 obligations — identifying whether your current setup exposes you under the new foreign importer framework and recommending structural changes where required
• Bond Position Assessment – We review whether your continuous bond retains validity under the new CBP approval criteria introduced by EO 14411, or whether you need to transition to single-entry bonds or submit a formal CBP approval application under 19 CFR Part 113
• CTPAT Broker Verification – We confirm whether your current US customs broker holds active CTPAT validation under 19 CFR Part 165

• Where they do not, we connect you with our network of CTPAT-validated brokers to ensure your entries remain compliant from the December 2026 enforcement date
• Entry Disclosure Preparation – We help you compile the new mandatory entry disclosures — including beneficial ownership data, import volume history, Manufacturer IDs, supply chain provenance records and foreign tax identification numbers — as required on CBP Form 7501 under the new entry summary rules
• HTS Classification & Valuation Audit – We review your current HTS classifications and declared customs values against CBP Informed Compliance Publications, identifying misclassification or undervaluation risk before penalties arise

• The reduced mitigation relief under EO 14411 makes proactive review essential
• FDA & FSMA Parallel Compliance – For food, supplement and medical device brands, we manage FDA Foreign Facility Registration under 21 CFR Part 1 Subpart H and FSVP compliance under 21 CFR Part 1 Subpart L in parallel — giving you a single compliance partner across both CBP and FDA obligations

What EO 14411 Actually Changes

EO 14411 doesn’t just tighten the rules — it removes tools foreign importers have leaned on for years. Informal entry is gone. Low-value shipments used to clear on a simplified process. Now every entry from a foreign importer needs full formal CBP entry — Form 7501, bond in place, licensed broker of record.

If you built your US logistics around informal or de minimis entry (e-commerce, Amazon FBA, SMEs), this is a rebuild, not a tweak. Continuous bonds no longer carry forward. They once covered a year of entries with no pre-approval. Now they need specific CBP sign-off — and CBP is re-reviewing existing holders. No valid bond at entry means held shipments and penalties.

Expect single-entry bonds as the default until CBP approves a continuous one. Beneficial ownership is now declared at entry. Borrowing from the Corporate Transparency Act playbook, CBP wants the real owners of the importing entity, cross-checked against your volume history and supply chain data. Import through a US subsidiary, a third-party IOR or a fulfilment intermediary?

Your ownership trail has to be accurate. Getting it wrong — even by accident — is far harder to mitigate now, making prior disclosure a key risk tool if your classification or valuation is uncertain.

• The 8 changes that matter:
• Every foreign-importer entry is now formal — informal entry is gone
• Continuous bonds need fresh CBP approval; old ones don’t carry forward
• CTPAT validation required at broker level — non-validated brokers are non-compliant
• Beneficial ownership must be disclosed at entry, even via a third-party IOR
• Manufacturer IDs, foreign tax IDs and supply chain data now mandatory on Form 7501
• Misclassification and undervaluation penalties are far harder to mitigate
• Food, supplement and device importers also face FDA FSMA inspections
• The 180-day window closes early December 2026 — be ready before then

Our EO 14411 Compliance Review: What We Arrange and Manage End-to-End

Step 1 1) Initial Compliance Gap Assessment

We begin with a structured review of your current US import setup mapping your existing arrangements against each of the key changes introduced by Executive Order 14411.

This is not a generic audit; it is a targeted assessment of the specific areas the order changes: your IOR structure, bond type and approval status, broker’s CTPAT validation, and your current entry documentation against the new disclosure requirements.

• Review of existing IOR arrangements under 19 USC 1484
• Bond type classification: continuous vs single-entry under 19 CFR Part 113
• Broker CTPAT status verification under 19 CFR Part 165
• Entry documentation gap analysis against EO 14411 disclosure requirements
• HTS classification spot-check and valuation risk assessment

Step 2 2) IOR Structure and Bond Remediation

Where gaps are identified — and in most cases involving foreign importers, they will be — we work with you to restructure your Importer of Record arrangement and address your bond position.

This may involve engaging a new CTPAT-validated customs broker, applying for CBP continuous bond approval under the new criteria, or transitioning to single-entry bonds as an interim measure while approval is sought. We manage the broker introduction and transition process on your behalf, ensuring continuity of entry filing during the remediation period.

• CTPAT-validated broker introduction and onboarding support
• CBP continuous bond approval application guidance under 19 CFR Part 113
• Single-entry bond transitional arrangement where required
• IOR structural recommendations for foreign-owned brands without a US entity

Step 3 3) Entry Disclosure Documentation Build

We help you compile and structure the new mandatory disclosure data required at entry under EO 14411. This includes beneficial ownership records cross-referenced against your corporate structure, Manufacturer ID (MID) codes for all foreign suppliers, foreign tax identification numbers for each entity in your supply chain, and import volume history documentation.

For brands that source from multiple factories — particularly in China and South-East Asia — this process requires systematic supplier data collection that we coordinate on your behalf.

• Beneficial ownership declaration preparation — aligned with FinCEN Corporate Transparency Act cross-references
• MID code verification and correction for all listed manufacturers
• Foreign tax identifier collection across your supplier base
• Supply chain provenance records structured for CBP Form 7501 compliance

Step 4 4) HTS Classification and Valuation Review

Given the substantially reduced mitigation pathways now available under EO 14411, a proactive HTS classification and customs valuation review is no longer optional — it is the single most effective way to protect against penalty exposure.

We review your product classifications against the Harmonized Tariff Schedule of the United States, cross-check declared transaction values against CBP valuation rules, and where uncertainty exists, recommend prior disclosure submissions to CBP before the entry is filed. This preserves mitigation options that would otherwise be lost at enforcement.

Step 5 5) FDA and FSMA Parallel Compliance Management

For food, supplement, cosmetic and medical device importers, Executive Order 14411 enforcement does not operate in isolation. FDA is simultaneously expanding its programme of unannounced foreign facility inspections under FSMA authority, targeting facilities registered under 21 CFR Part 1 Subpart H.

Brands that are out of compliance with FSVP obligations under 21 CFR Part 1 Subpart L — or whose FDA Foreign Facility Registration is lapsed or inaccurate — face compounded risk from two federal enforcement programmes running concurrently.

As your FDA Agent and FSVP compliance partner, we manage both simultaneously, ensuring your CBP and FDA status are aligned ahead of the December 2026 implementation deadline.

What’s Included in GIA’s EO 14411 Compliance Service

Customs Compliance Gap Analysis

A structured, five-point assessment of your current US import setup against the specific changes introduced by Executive Order 14411 — covering IOR structure, bond position, broker CTPAT status, entry disclosures and HTS classification risk.

CTPAT-Validated Broker Introduction

Where your current customs broker does not hold active CTPAT validation under 19 CFR Part 165, we introduce you to a validated broker from our established network and manage the transition to ensure continuity of entry filing before the December 2026 deadline.

Continuous Bond Advisory and Application Support

We assess whether your existing continuous bond retains validity under the new CBP approval criteria, advise on transitional single-entry bond arrangements, and support any formal CBP continuous bond approval application under 19 CFR Part 113.

Entry Disclosure Documentation Package

We compile and structure the new mandatory CBP entry disclosures — including beneficial ownership data, Manufacturer ID codes, foreign tax identifiers and supply chain provenance records — ready for integration into your CBP Form 7501 entry summaries.

HTS Classification and Valuation Audit

A targeted review of your product HTS codes against the Harmonized Tariff Schedule of the United States and declared customs values against CBP valuation rules — with prior disclosure recommendations where misclassification or undervaluation risk is identified.

FDA Agent and FSVP Parallel Management

For food, supplement and medical device brands, we manage FDA Foreign Facility Registration under 21 CFR Part 1 Subpart H and FSVP compliance under 21 CFR Part 1 Subpart L alongside your CBP compliance — providing a single point of accountability across both enforcement frameworks.

Key changes under EO 14411 that affect your imports today

• Informal entry abolished — formal CBP entry required for all shipments under 19 CFR Part 142
• Continuous bonds restricted to CBP-approved importers — existing bonds may not carry forward automatically
• CTPAT validation required at customs broker level under 19 CFR Part 165
• Beneficial ownership, MID codes, foreign tax identifiers and supply chain data now mandatory at entry
• Reduced mitigation relief for HTS misclassification and customs undervaluation — penalties are harder to negotiate
• FDA unannounced foreign facility inspections expanding under FSMA — compounded risk for food and supplement brands
• IOR arrangements using third-party providers must be re-evaluated under the revised 19 USC 1484 framework
• December 2026 implementation deadline is firm — structural changes must be in place before enforcement begins How GIA addresses each risk area:
• Compliance gap assessment: five-point audit of your current customs setup against EO 14411 requirements
• Broker review: CTPAT validation check on your current broker with validated alternative introduction where required
• Bond advisory: review of your continuous bond status and CBP approval application support under 19 CFR Part 113
• Disclosure documentation: compilation of beneficial ownership, MID codes, foreign tax identifiers and supply chain records
• HTS and valuation audit: proactive classification and value review with prior disclosure recommendations where risk is identified
• FDA parallel management: FDA Agent, Foreign Facility Registration and FSVP compliance managed alongside CBP obligations

What Is EO 14411 — And Why Now?

Signed on 3 June 2026 under the title Strengthening Customs Enforcement, EO 14411 is the biggest shake-up of US import rules since the Trade Act of 2002.

It doesn’t create new law — it runs on existing authority (19 USC 1484, plus 19 CFR Parts 113 and 142) — but it tells CBP to enforce that authority far harder, with little patience for the informal arrangements foreign importers have leaned on for years. The 180-day clock started on 3 June, so everything is fully live by early December 2026.

For foreign importers, that’s four immediate risk areas: Informal entry is gone.

• Every shipment — low-value e-commerce, Amazon FBA restocks, all of it — now needs a formal CBP entry with full docs, a licensed broker and bond coverage
• Continuous bonds no longer self-renew

• They need active CBP approval, and it isn’t automatic
• Brokers must be CTPAT-validated

• Many smaller brokers serving UK, EU and Asian brands aren’t — which quietly makes their entries non-compliant
• Beneficial ownership is now disclosed at entry

Borrowing from the FinCEN Corporate Transparency Act, CBP wants entity transparency most importers’ paperwork can’t yet deliver. And it doesn’t stop at customs.

CBP’s crackdown runs alongside an FDA push on unannounced foreign facility inspections under FSMA — so a single shipment can trigger a CBP bond or disclosure failure and FDA action on an unregistered facility or lapsed FSVP at the same time. Treating customs and FDA as separate tracks is already a losing position.

End-to-end compliance is now the baseline for selling into the US.

• What EO 14411 changes today:
• Informal entry abolished — formal CBP entry for all foreign-importer shipments
• Continuous bonds restricted to CBP-approved importers; old ones may not carry forward
• CTPAT validation required at broker level
• Beneficial ownership, MID codes, foreign tax IDs and supply chain data mandatory at entry
• Misclassification and undervaluation penalties far harder to mitigate
• FDA foreign facility inspections expanding under FSMA — compounded risk for food and supplement brands
• Third-party IOR arrangements must be re-evaluated under the revised 19 USC 1484 approach
• December 2026 deadline is firm — be ready before enforcement begins How GIA covers each risk:
• Compliance gap assessment — five-point audit against EO 14411
• Broker review — CTPAT check on your broker, with a validated alternative if needed
• Bond advisory — continuous bond review and CBP approval support
• Disclosure documentation — beneficial ownership, MID codes, tax IDs and supply chain records compiled
• HTS and valuation audit — proactive review with prior disclosure where risk shows
• FDA parallel management — FDA Agent, Foreign Facility Registration and FSVP run alongside CBP Global Import Agent works with over 500 brands across the UK, EU, US and Asia on FDA, FSVP and customs compliance

Our existing client relationships mean we already understand your supply chain, your product categories and your regulatory exposure — we are not starting from scratch when we assess your EO 14411 position. ★ CBP and FDA Expertise Under One Roof Most compliance providers cover either customs or FDA — not both.

Because EO 14411 enforcement runs in parallel with an FDA foreign inspection surge, having a single partner accountable for both CBP and FDA compliance is a material operational advantage. We manage FDA Agent obligations under 21 CFR Part 1 Subpart H and FSVP programmes under Subpart L alongside CBP compliance — you deal with one team, not two.

★ Proactive, Not Reactive The importers who will be caught out by EO 14411 are those whose freight forwarders and brokers are not proactively flagging the structural changes required. Our model is built on dedicated account management and active compliance monitoring — we identify the gap before CBP does, not after a shipment is held or a penalty notice is issued.

If you import into the US — whether directly, through Amazon FBA, or via a third-party IOR arrangement — it is worth taking 20 minutes to establish whether your current setup is still compliant under Executive Order 14411.

The December 2026 implementation deadline is closer than it looks, and the structural changes required — broker transitions, bond applications, disclosure documentation — all take lead time that cannot be recovered once enforcement begins.

Contact our team to request a no-obligation compliance gap review, and we will tell you plainly where your risks are and what needs to change.